logo

MANGALAM vs SUNPHARMA: Stock Comparison

MANGALAM DRUG & CHEM vs SUN PHARMACEUTICAL IND LUpdated 22 Oct 26, 4:08 PM ISTNSE & company filings

SUN PHARMACEUTICAL IND L is the larger company by market capitalisation. SUN PHARMACEUTICAL IND L shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

MANGALAM leads 0; SUNPHARMA leads 9 of 11

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

MANGALAMSUNPHARMA

Valuation lens

What price are you paying?

Market CapContext only
₹47 Cr
₹4.21 L Cr
P/E RatioSame reading
—
34.79x
P/B RatioSame reading
—
5.04x
EPSSUNPHARMA has the higher reading
₹-4.83
₹50.46 ✓
Book ValueContext only
₹65.11
₹348.31
Dividend YieldSUNPHARMA has the higher reading
0%
0.92% ✓

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
SUNPHARMA is the larger company
₹4.21 L Cr vs ₹47 Cr
EPS
SUNPHARMA has higher earnings per share
₹50.46 vs ₹-4.83
Dividend Yield
SUNPHARMA has a higher dividend yield
0.92% vs 0%
Revenue Growth (TTM YoY)
SUNPHARMA has faster revenue growth
12.8% vs -7.5%
EPS Growth (TTM YoY)
SUNPHARMA has faster EPS growth
25.6% vs 0%
ROE
SUNPHARMA has a higher ROE
11.76% vs -42.41%
ROCE
SUNPHARMA has a higher ROCE
9.6% vs -15.52%
Net Margin
SUNPHARMA has a higher net margin
18.56% vs -19.13%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricMANGALAMSUNPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricMANGALAMSUNPHARMA
Live Price₹29.57₹1,758
Day Change-2.79%0.74%
Volume11,15717.79 L
52-Week High₹71.99₹2,046.9
52-Week Low₹22.8₹1,583.7
Distance from 52W High-58.92%-14.11%

Valuation

MetricMANGALAMSUNPHARMA
Market Cap₹47 Cr₹4.21 L Cr
P/E Ratio—34.79x
P/B Ratio—5.04x
EPS₹-4.83₹50.46
Book Value₹65.11₹348.31
Dividend Yield0%0.92%

Growth

MetricMANGALAMSUNPHARMA
Revenue Growth (TTM YoY)-7.5%12.8%
EPS Growth (TTM YoY)0%25.6%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricMANGALAMSUNPHARMA
ROE-42.41%11.76%
ROCE-15.52%9.6%
Net Margin-19.13%18.56%
Operating Margin-13.69%22.81%
Debt to Equity0.99x0.6x

Shareholding

As of Sep 2026 • change vs previous quarter
MetricMANGALAMSUNPHARMA
Promoter Holding35.65%52.68%▼ 1.8 pp
FII Holding0.11%14.36%▼ 0.17 pp
DII Holding0%22.27%▲ 0.09 pp
Public Holding64.24%10.7%▲ 1.89 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: MANGALAM DRUG & CHEM and SUN PHARMACEUTICAL IND L.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.